The Science of Psilocybin.
And Beyond.
Deep psilocybin neuroscience — receptor binding, neuroplasticity, clinical protocols, veteran restoration — plus research on other psychedelic compounds. Published daily. Every claim backed by peer-reviewed data.
Featured Articles
Psilocybin and Bipolar Disorder: The Field's Hardest Open Question
The first peer-reviewed psilocybin trial that did not exclude bipolar disorder posted MADRS −24 (Cohen d=4.08) and zero hypomanic switches. The exclusion has stood since 2006. The reasoning behind it has not caught up with the data.
Psilocybin and Parkinson's Disease: The Neuroscience of a Possible Disease-Modifying Therapy
The first psychedelic ever tested in a neurodegenerative disease. Bradley 2025 UCSF trial: −9.3 MADRS, −4.6 motor improvement, zero serious adverse events. α-synuclein silences TrkB; psilocin reactivates it. The cleanest disease-modifying logic chain in psychedelic neuroscience.
Veterans and Psilocybin: The Neuroscience of Healing the Wounds of War
22 veterans die by suicide every day. Combat trauma damages four neural systems at once — amygdala, default mode network, fear-extinction circuit, neuroinflammation. Psilocybin is the first intervention demonstrated to engage all four. The full master review on veterans + psilocybin science.
Psilocybin and Alzheimer’s Disease: The Neuroplasticity Hypothesis
BDNF collapses 30–40% in Alzheimer's brains. Psilocybin triggers the largest known BDNF surge. Tau phosphorylation fell ~35% in mouse models. Four mechanisms, one disease — the most unexpected convergence in neurodegeneration research.
The Pineal Gland: Science vs Myth
A pea-sized gland at the geometric center of your brain. Descartes called it the seat of the soul. Strassman called it the DMT factory. Borjigin's lab found DMT-producing enzymes everywhere — not just the pineal. The myth, the data, and the truth in between.
5-MeO-DMT vs Psilocybin: Two Doors to the Same Room
Six hours vs fifteen minutes. Davis (2018) showed 5-MeO-DMT mystical intensity equals high-dose psilocybin. GH001 hit -15.5 MADRS in Phase 2b TRD. The pharmacology, phenomenology, and clinical data on two doors into the same room.
Psilocybin and Nicotine Addiction: How a Single Session Breaks the Hardest Habit
80% quit rate after 2-3 sessions vs 13% for nicotine patches. Johns Hopkins researchers have cracked the neuroscience of tobacco addiction — and it starts with the default mode network.
Psilocybin and Anxiety: The Neuroscience of Dissolving Fear
80% of participants reported sustained anxiety relief after a single psilocybin session. The amygdala quiets, the default mode network resets, and fear patterns built over decades dissolve.
Psilocybin and Neurogenesis: How Psychedelics Grow New Brain Cells
The adult brain was supposed to stop growing new neurons. Psilocybin proved otherwise. Hippocampal neurogenesis surges after a single dose — the biological mechanism behind the antidepressant effect.
Precision-dosed psilocybin
mushroom products.
Engineered for daily ritual, neural reconstruction, and sustained cognitive performance. Lab-tested. Ceremony-ready.
SHOP OOTW MUSHROOM PRODUCTSAbout Out Of This World
We operate at the threshold where ancient plant wisdom meets modern clinical observation. OOTW JOURNAL exists because psilocybin science deserves a dedicated platform — one that treats the research with the seriousness it demands. No hype. No speculation. Only mechanisms, clinical data, and protocols.
Our primary focus is psilocybin: receptor pharmacology, neuroplasticity, BDNF expression, veteran restoration, daily microdosing protocols. We also cover adjacent psychedelic compounds and consciousness research. New articles published daily. Every claim backed by peer-reviewed data.
Shop OOTW Mushroom Products open_in_new